Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma

Li Tzong Chen, Jaw Town Lin, John Jen Tai, Gran Hum Chen, Hong Zen Yeh, Sheng Shun Yang, Hsiu Po Wang, Sung Hsin Kuo, Bor Shyang Sheu, Chang Ming Jan, Wen Ming Wang, Tsang En Wang, Chew Wun Wu, Chi Long Chen, Ih Jen Su, Jacqueline Whang-Peng, Ann Lii Cheng

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Background: Several independent clinical studies have reported that Helicobacter pylori eradication therapy could achieve complete remission in some patients with H. pylori-positive early-stage gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Methods: To compare the long-term results of anti-H. pylori therapy in early-stage, gastric low-grade and high-grade transformed MALT lymphoma, two multicenter prospective studies of anti-H. pylori therapy for early-stage gastric lymphoma conducted in Taiwan, one for low-grade MALT lymphoma, with 34 patients enrolled from March 1996 through April 1999, and one for high-grade transformed tumors (diffuse large B-cell lymphoma with features of MALT, DLBCL[MALT] lymphoma), with 24 patients enrolled since June 1995, were directly compared. In both studies, patients generally received 2 weeks of antibiotics and had multiple sequential follow-up endoscopic examinations until complete histologic remission (CR) or disease progression; patients were monitored through January 31, 2004. CR was defined as regression of lymphoid infiltration to Wotherspoon's score of 2 or less on all pathologic sections of endoscopic biopsy specimens. All statistical tests were two-sided. Results: The H. pylori-positive rate among the 34 low-grade patients was 94% (32 of 34). All 24 selected high-grade patients were H. pylori positive. H. pylori was eradicated in 97% (30 of 31) of evaluable H. pylori-positive low-grade patients and in 92% (22 of 24) of high-grade patients, which led to CR in 80% (24 of 30, 95% confidence interval [CI] = 65% to 95%) and 64% (14 of 22, 95% CI = 42% to 86%) of patients, respectively. None of the five patients who were either initially H. pylori negative or had persistent H. pylori infection after antibiotics achieved CR. After median follow-up of more than 5 years in complete responders, tumor recurrence was observed in three (13%) low-grade patients but not in high-grade patients. Conclusions: Anti-H. pylori therapy may be considered as one of the treatment options for early-stage H. pylori-positive gastric DLBCL(MALT), and large-scale prospective studies to validate its use as first-line therapy for such tumors should be undertaken.

Original languageEnglish
Pages (from-to)1345-1353
Number of pages9
JournalJournal of the National Cancer Institute
Volume97
Issue number18
DOIs
Publication statusPublished - Sep 2005

Fingerprint

Marginal Zone B-Cell Lymphoma
Helicobacter pylori
Stomach
Therapeutics
Lymphoid Tissue
Gastric Mucosa
Prospective Studies
Confidence Intervals
Anti-Bacterial Agents
Neoplasms
Lymphoma, Large B-Cell, Diffuse
Helicobacter Infections
Taiwan
Non-Hodgkin's Lymphoma
Multicenter Studies
Disease Progression

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. / Chen, Li Tzong; Lin, Jaw Town; Tai, John Jen; Chen, Gran Hum; Yeh, Hong Zen; Yang, Sheng Shun; Wang, Hsiu Po; Kuo, Sung Hsin; Sheu, Bor Shyang; Jan, Chang Ming; Wang, Wen Ming; Wang, Tsang En; Wu, Chew Wun; Chen, Chi Long; Su, Ih Jen; Whang-Peng, Jacqueline; Cheng, Ann Lii.

In: Journal of the National Cancer Institute, Vol. 97, No. 18, 09.2005, p. 1345-1353.

Research output: Contribution to journalArticle

Chen, LT, Lin, JT, Tai, JJ, Chen, GH, Yeh, HZ, Yang, SS, Wang, HP, Kuo, SH, Sheu, BS, Jan, CM, Wang, WM, Wang, TE, Wu, CW, Chen, CL, Su, IJ, Whang-Peng, J & Cheng, AL 2005, 'Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma', Journal of the National Cancer Institute, vol. 97, no. 18, pp. 1345-1353. https://doi.org/10.1093/jnci/dji277
Chen, Li Tzong ; Lin, Jaw Town ; Tai, John Jen ; Chen, Gran Hum ; Yeh, Hong Zen ; Yang, Sheng Shun ; Wang, Hsiu Po ; Kuo, Sung Hsin ; Sheu, Bor Shyang ; Jan, Chang Ming ; Wang, Wen Ming ; Wang, Tsang En ; Wu, Chew Wun ; Chen, Chi Long ; Su, Ih Jen ; Whang-Peng, Jacqueline ; Cheng, Ann Lii. / Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. In: Journal of the National Cancer Institute. 2005 ; Vol. 97, No. 18. pp. 1345-1353.
@article{e72ee72e655a495cb5e32cd0f65042c4,
title = "Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma",
abstract = "Background: Several independent clinical studies have reported that Helicobacter pylori eradication therapy could achieve complete remission in some patients with H. pylori-positive early-stage gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Methods: To compare the long-term results of anti-H. pylori therapy in early-stage, gastric low-grade and high-grade transformed MALT lymphoma, two multicenter prospective studies of anti-H. pylori therapy for early-stage gastric lymphoma conducted in Taiwan, one for low-grade MALT lymphoma, with 34 patients enrolled from March 1996 through April 1999, and one for high-grade transformed tumors (diffuse large B-cell lymphoma with features of MALT, DLBCL[MALT] lymphoma), with 24 patients enrolled since June 1995, were directly compared. In both studies, patients generally received 2 weeks of antibiotics and had multiple sequential follow-up endoscopic examinations until complete histologic remission (CR) or disease progression; patients were monitored through January 31, 2004. CR was defined as regression of lymphoid infiltration to Wotherspoon's score of 2 or less on all pathologic sections of endoscopic biopsy specimens. All statistical tests were two-sided. Results: The H. pylori-positive rate among the 34 low-grade patients was 94{\%} (32 of 34). All 24 selected high-grade patients were H. pylori positive. H. pylori was eradicated in 97{\%} (30 of 31) of evaluable H. pylori-positive low-grade patients and in 92{\%} (22 of 24) of high-grade patients, which led to CR in 80{\%} (24 of 30, 95{\%} confidence interval [CI] = 65{\%} to 95{\%}) and 64{\%} (14 of 22, 95{\%} CI = 42{\%} to 86{\%}) of patients, respectively. None of the five patients who were either initially H. pylori negative or had persistent H. pylori infection after antibiotics achieved CR. After median follow-up of more than 5 years in complete responders, tumor recurrence was observed in three (13{\%}) low-grade patients but not in high-grade patients. Conclusions: Anti-H. pylori therapy may be considered as one of the treatment options for early-stage H. pylori-positive gastric DLBCL(MALT), and large-scale prospective studies to validate its use as first-line therapy for such tumors should be undertaken.",
author = "Chen, {Li Tzong} and Lin, {Jaw Town} and Tai, {John Jen} and Chen, {Gran Hum} and Yeh, {Hong Zen} and Yang, {Sheng Shun} and Wang, {Hsiu Po} and Kuo, {Sung Hsin} and Sheu, {Bor Shyang} and Jan, {Chang Ming} and Wang, {Wen Ming} and Wang, {Tsang En} and Wu, {Chew Wun} and Chen, {Chi Long} and Su, {Ih Jen} and Jacqueline Whang-Peng and Cheng, {Ann Lii}",
year = "2005",
month = "9",
doi = "10.1093/jnci/dji277",
language = "English",
volume = "97",
pages = "1345--1353",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma

AU - Chen, Li Tzong

AU - Lin, Jaw Town

AU - Tai, John Jen

AU - Chen, Gran Hum

AU - Yeh, Hong Zen

AU - Yang, Sheng Shun

AU - Wang, Hsiu Po

AU - Kuo, Sung Hsin

AU - Sheu, Bor Shyang

AU - Jan, Chang Ming

AU - Wang, Wen Ming

AU - Wang, Tsang En

AU - Wu, Chew Wun

AU - Chen, Chi Long

AU - Su, Ih Jen

AU - Whang-Peng, Jacqueline

AU - Cheng, Ann Lii

PY - 2005/9

Y1 - 2005/9

N2 - Background: Several independent clinical studies have reported that Helicobacter pylori eradication therapy could achieve complete remission in some patients with H. pylori-positive early-stage gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Methods: To compare the long-term results of anti-H. pylori therapy in early-stage, gastric low-grade and high-grade transformed MALT lymphoma, two multicenter prospective studies of anti-H. pylori therapy for early-stage gastric lymphoma conducted in Taiwan, one for low-grade MALT lymphoma, with 34 patients enrolled from March 1996 through April 1999, and one for high-grade transformed tumors (diffuse large B-cell lymphoma with features of MALT, DLBCL[MALT] lymphoma), with 24 patients enrolled since June 1995, were directly compared. In both studies, patients generally received 2 weeks of antibiotics and had multiple sequential follow-up endoscopic examinations until complete histologic remission (CR) or disease progression; patients were monitored through January 31, 2004. CR was defined as regression of lymphoid infiltration to Wotherspoon's score of 2 or less on all pathologic sections of endoscopic biopsy specimens. All statistical tests were two-sided. Results: The H. pylori-positive rate among the 34 low-grade patients was 94% (32 of 34). All 24 selected high-grade patients were H. pylori positive. H. pylori was eradicated in 97% (30 of 31) of evaluable H. pylori-positive low-grade patients and in 92% (22 of 24) of high-grade patients, which led to CR in 80% (24 of 30, 95% confidence interval [CI] = 65% to 95%) and 64% (14 of 22, 95% CI = 42% to 86%) of patients, respectively. None of the five patients who were either initially H. pylori negative or had persistent H. pylori infection after antibiotics achieved CR. After median follow-up of more than 5 years in complete responders, tumor recurrence was observed in three (13%) low-grade patients but not in high-grade patients. Conclusions: Anti-H. pylori therapy may be considered as one of the treatment options for early-stage H. pylori-positive gastric DLBCL(MALT), and large-scale prospective studies to validate its use as first-line therapy for such tumors should be undertaken.

AB - Background: Several independent clinical studies have reported that Helicobacter pylori eradication therapy could achieve complete remission in some patients with H. pylori-positive early-stage gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Methods: To compare the long-term results of anti-H. pylori therapy in early-stage, gastric low-grade and high-grade transformed MALT lymphoma, two multicenter prospective studies of anti-H. pylori therapy for early-stage gastric lymphoma conducted in Taiwan, one for low-grade MALT lymphoma, with 34 patients enrolled from March 1996 through April 1999, and one for high-grade transformed tumors (diffuse large B-cell lymphoma with features of MALT, DLBCL[MALT] lymphoma), with 24 patients enrolled since June 1995, were directly compared. In both studies, patients generally received 2 weeks of antibiotics and had multiple sequential follow-up endoscopic examinations until complete histologic remission (CR) or disease progression; patients were monitored through January 31, 2004. CR was defined as regression of lymphoid infiltration to Wotherspoon's score of 2 or less on all pathologic sections of endoscopic biopsy specimens. All statistical tests were two-sided. Results: The H. pylori-positive rate among the 34 low-grade patients was 94% (32 of 34). All 24 selected high-grade patients were H. pylori positive. H. pylori was eradicated in 97% (30 of 31) of evaluable H. pylori-positive low-grade patients and in 92% (22 of 24) of high-grade patients, which led to CR in 80% (24 of 30, 95% confidence interval [CI] = 65% to 95%) and 64% (14 of 22, 95% CI = 42% to 86%) of patients, respectively. None of the five patients who were either initially H. pylori negative or had persistent H. pylori infection after antibiotics achieved CR. After median follow-up of more than 5 years in complete responders, tumor recurrence was observed in three (13%) low-grade patients but not in high-grade patients. Conclusions: Anti-H. pylori therapy may be considered as one of the treatment options for early-stage H. pylori-positive gastric DLBCL(MALT), and large-scale prospective studies to validate its use as first-line therapy for such tumors should be undertaken.

UR - http://www.scopus.com/inward/record.url?scp=25144464528&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25144464528&partnerID=8YFLogxK

U2 - 10.1093/jnci/dji277

DO - 10.1093/jnci/dji277

M3 - Article

C2 - 16174856

AN - SCOPUS:25144464528

VL - 97

SP - 1345

EP - 1353

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 18

ER -